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Abstract
Purpose
To develop an anesthetic mucoadhesive film containingAcmella oleracea (jambu) extract
for topical use on oral mucosa.
Methods
Ethanolic extracts from aerial parts of jambu were prepared by maceration. Pigment
removal was obtained by adsorptionwith activated carbon. Threemucoadhesive films were
developed using a film castingmethod: 10 or 20% of crude jambu extract (10% JB and 20%
JB), and 10% of crude jambu extract treatedwith activated carbon (10% JBC). Themucoad-
hesive films were characterized regarding their uniformity, thickness, pH, and spilanthol
content, and their stability was evaluated during 120 days. Gas chromatography was used
to quantify the amount of spilanthol. In vitro tests determined the permeationof spilanthol
across pig esophageal epitheliummucosa in Franz diffusion cells. Topical anesthetic effi-
cacy was assessed in vivo using a tail flick test in mice.
Results
The threemucoadhesive films showed physical stability and visual appearances suitable
for use on oral mucosa. The permeationstudy revealed that the spilanthol from 10% JBC
presented higher flux and permeability coefficient values, compared to 10% or 20% JB
(p < 0.001). Moreover, 10% JBC showed better topical anesthetic efficacy than the other
films (p < 0.01).
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Conclusion
Mucoadhesive film containing crude extract of jambu treatedwith activated carbon is a
potential alternative for oral, topical use, encouraging future clinical studies.
1. Introduction
A significant fear-triggering agent during dental treatment is the perceived pain during anes-
thetic injections, which is a source for fear and anxiety that affects up to 30% of the global pop-
ulation [1–3]. In fact, such painful procedures have significantly inhibited patients from
seeking appropriate dental treatment [4–7]. Local anesthetics cause a loss of sensitivity by act-
ing on the nerve cell membrane, preventing the generation and conduction of nerve impulses
[8]. Topical application of local anesthetics on oral mucosa generally produces superficial anes-
thesia, useful to reduce the pain during needle insertion or other minimally invasive dental pro-
cedures. To achieve an effective topical anesthesia, it is necessary that the topical anesthetic
remains in the place of application for a minimum of two minutes [2].
Despite not being designed for oral use, the eutecticmixture of 2.5% lidocaine and 2.5% pri-
locaine (EMLACream1) is currently considered the most effective and potent topical anes-
thetic on oral mucosa [9–14]. Many studies have shown the superior topical anesthesia
effectiveness of EMLA in dental procedures in comparison with commercial topical anesthet-
ics, such as 5% lidocaine or 20% benzocaine. The high costs of commercial-synthetic topical
anesthetics, which are economically viable only in small portions of the body, along with
reports of severe neurotoxicity and cardiotoxicity induced by lidocaine and other topical anes-
thetics [15–17], justify the development of new substitutes. It is, therefore, relevant and timely
to identify and develop new anesthetics suitable for minimizing oral pain associatedwith dental
procedures [3, 18–20].
The constant interest in natural pharmaceuticals has led to great investigation in plant prod-
ucts.Acmella oleracea (L.) R.K. Jansen, also referred to as Spilanthes acmella L.Murray, is a native
South American herb, being very common throughout Southeast Asia [21, 22]. Popularly known
as jambu or paracress, it is traditionally used by the northern Brazilian population as a food spice
and for the treatment of toothaches and other ailments affecting gums and throat.
Several compounds have been identified in jambu, such as β-caryophyllene, limonene, and
thymol in the essential oil, along with vanillic acid, trans-ferulic acid, stigmasterol, β-sitosterol,
rhamnogalacturonan, scopoletin and alkyl amides in extracts [23–27]. Spilanthol (synonym:
affinin), an N-alkyl amide, is one of the bioactive compounds of jambu, being used as flavoring
agent in soups, processed vegetables, condiments, chewing gum and dentifrices [28]. When
ingested, it causes tingling, numbness and increased salivation [29, 30]. The high concentration
of spilanthol found in this species is responsible for both analgesic and anti-inflammatory
effects [31, 32]. Studies have evaluated the antinociceptive activity of jambu, and the proposed
mechanism of action include the modulation or blocking of transient receptor potential chan-
nels subfamily V member 1 (TRPV1) and subfamily A member 1 (TRPA1) [33] and the
increased release of gamma-aminobutyric acid [34].
The anesthetic activity of jambu was previously described [35, 36]. Jambu is also classified
as safe (GRAS #3783) by the Flavor and ExtractManufacturers Association (FEMA) [37] and
the European Food Safety Authority (EFSA) [38]. It presents low toxicity [33, 39, 40] and a
widespread popular use. Considering the current lack of effective formulations for topical anes-
thesia on oral mucosa, jambu is a good candidate for topical anesthesia.
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During the development of formulations describedhere, chitosan was used as a film-form-
ing agent due to its biocompatibility, biodegradability, and non-toxicity. Furthermore, chitosan
exhibits buccal mucoadhesive capacity, interacting with negatively-charged groups of the epi-
thelium surface. These characteristics contributed to the selection of chitosan as the film-form-
ing polymer in this study [41, 42].
The aim of the present study was to develop a mucoadhesive film for oral anesthetic applica-
tion that could be used as a pre-anesthetic before injection in dental procedures.
2. Material andMethods
2.1 Materials
All the reagents and solvents used were analytical or chromatographic grade. The materials
used were as follows: chitosan (deacetylation degree> 75%) (Sigma-Aldrich1, MO, USA);
Transcutol1 (ethoxydiglycol) (Gattefossé1, Lyon, France); methylparaben, glacial acetic acid,
ethanol, ethyl acetate, n-hexane, and methanol (Synth1, São Paulo, Brazil); activated carbon
(specification type in patent number BR102014022486-6); diatomaceous earth (Celite1 545)
(Nuclear1, São Paulo, Brazil); eutecticmixture of 2.5% lidocaine and 2.5% prilocaine (5%
EMLA1 cream—AstraZeneca1, São Paulo, Brazil); chromatography grademethanol (J.T.
Baker1, PA, USA).
2.2 Production of the CrudeEthanolic Extract of Jambu
The plant material used in this study was obtained from the experimental field cultivation at
the Chemical, Biological, and Agricultural Research Center (CPQBA), University of Campinas
(UNICAMP), located in Paulinia (São Paulo State, Brazil; 22° 47' 52" S, 47° 6' 49" W). The iden-
tificationwas confirmed by Dr. John F. Pruski of Missouri Botanical Garden, USA. A voucher
specimen is deposited in the Herbarium of UNICAMP, under catalog #181452. The aerial
parts of the jambu were dried,milled, and extractionwas performed under mechanical agita-
tion with 95% ethanol (1:5 w/v) in a stainless steel tank for 1.5 h. The remaining residue was
separated by filtration, and the extraction process was repeated two more times. The final
material was filtered, combined, concentrated under vacuum, and then lyophilized until dry-
ness, being used to determine the final drymass by weighing, to calculate the yield value. The
process yield was determined by the relation between the aerial material used and the final dry
mass of the extract. The estimated concentration of spilanthol in the extract was 3%. It was
stored in the refrigerator at 8°C until treatment with activated carbon.
2.2.1 Extract treatment with activated carbon. The extraction procedure was repeated to
confirm the reproducibility of the process, but without the drying step. The extracts obtained
were then combined and filtered, being added 4% (w/w) of activated carbon (Fig 1). The mix-
ture was stirred and treated using a particulate activated carbon [43]. The extract was
Fig 1. Illustration of the crude extract treatmentprocesswith activated carbon.
doi:10.1371/journal.pone.0162850.g001
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concentrated under vacuum, lyophilized to dryness, and stored in the refrigerator at 8°C until
further use.
2.3 Spilanthol Analysis
Analysis of spilanthol in the extract and mucoadhesive films was performed using a gas chro-
matograph coupled to a mass spectrometer (GC-MS, Agilent1 5890 Series II with Agilent1
5970 EI 70eVmass selective detector). The GCwas equipped with a fused silicaWCOT column
(Agilent1 HP5-MS, 30 m x 0.25 mm x 0.25 μm). The analysis conditions were: injector tem-
perature of 220°C, detector temperature of 250°C, temperature program 60–240°C at 3°C/min,
sample injection using split mode with 1:40 ratio, helium as carrier gas (0.7 bar, 1 mL/min).
A calibration curvewas prepared for the analytical determination of spilanthol, using spi-
lanthol isolated with a centrifugal partition chromatograph (Model 250-SCPC/Spot Prep II1,
Armen, Saint-Ave, France) equipped with a quaternary pump, UV/Vis detector, and a fraction
collector. The purity of 95.1% was found using GC-FIDwith area normalization. A stock solu-
tion of known concentration was prepared, followed by dilutions performed in volumetric
flasks. The limit of detection (0.26 μg.mL-1 / LOD) and limit of quantification (0.86 μg.mL-1 /
LOQ) was calculated based on the standard deviation of the response and the slope using three
independent analytical curves. LOD and LOQwere calculated as 3 and 10 times, respectively,
the standard deviation of the response/slope of the calibration curve [44].
2.4 Preparation of Mucoadhesive Films ContainingAcmella Oleracea
The mucoadhesive films were prepared using the casting technique resulting in a gel (Fig 2).
Briefly, chitosan (1 g) was dissolved in 1% (v/v) acetic acid solution, with the aid of a
Fig 2. Illustration of themucoadhesive film production.
doi:10.1371/journal.pone.0162850.g002
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mechanical homogenizer, and the solution was poured into molds (polystyrene Petri dishes).
The final step in the mucoadhesive films production was carried out in a gravity convection
drying oven at 40°C for 30 h. Jambu extracts at concentrations of 10% or 20%, with 0.1% of
methylparaben and 5% of transcutol were mixed with chitosan gel prepared previously accord-
ing to patent number BR102014022486-6 [43].
The mucoadhesive films used for the in vitro and in vivo assays were prepared with 10%
crude extract of jambu (10% JB), 20% crude extract of jambu (20% JB), or 10% crude extract of
jambu treated with 4% of activated carbon (10% JBC).
2.5 Mucoadhesive Films Characterization
Physicochemical evaluation of the mucoadhesive films considered the uniformity of weight
and thickness, pH, spilanthol content, and stability.
The mucoadhesive films were cut with a circular punch (15 mm diameter), the mass was
measured using an analytical balance (Mettler-Toledo1, São Paulo, Brazil), and the thickness
was measured using a digital pachymeter (Model Cal II, Tesa1, Renens, Switzerland).
The physicochemical stability of the mucoadhesive films was evaluated by packing the
materials in waterproof aluminum-lined plastic containers with hermetic closures, and storing
them at 40 ± 1°C for 120 days in a climate chamber with no humidity control. Samples were
analyzed at 0 and 120 days, considering their appearance, pH, and spilanthol content. The tests
were performed in triplicate.
The pH was measured in accordance with the Brazilian Pharmacopeia method [45]. Briefly,
deionizedwater was added to the mucoadhesive films at 1% (w/w), the mixture was ultrasoni-
cated for 2 min, and the pH was measured at room temperature with a pH-meter previously
calibrated at pH 7 and 4.
For the determination of spilanthol content, a knownmass of mucoadhesive films was
added to 1% (m/m) methanol and ultrasonicated for 10 min, followed by filtration through a
0.45 μmmembrane filter. The spilanthol quantification was performed according to the analyt-
ical conditions described in Section 2.3.
2.6 In vitro Permeation Studies
In vitro permeation studies were carried out using Franz-type vertical diffusion cells with per-
meation area of 0.6 cm2 and receptor compartment volume of 4.2 mL. The assays were per-
formed using pig esophagus epithelium obtained from a local slaughterhouse (Frigar
Abatedouro Industria e Comercio de Conservas Ltda–ME, located in Sousas-Pedreira Road,
Sao Paulo St Brazil, 22° 51' 50.2" S, 46° 59' 59.3" W), according to the method described by Diaz
del Consuelo (2005) [46]. The use of pig esophageal epithelium was demonstrated to be an
equivalent barriermodel to buccal epithelium, since it has similar histological characteristics,
permeability, and epithelium composition [46–48]. Moreover, esophageal mucosa has some
advantages including larger surface area, absence of damage caused by mastication and easy
preparation [46].
Briefly, within 2 h of slaughter, the pig esophageal mucosa was carefully separated from the
surrounding tissue with a scalpel. Mucosae with any visual damage at the surface were dis-
carded. The epithelium was separated from the connective tissue after immersion in deionized
water at 60°C for 2 min and it was used immediately. This temperature was demonstrated to be
unable to alter integrity or permeability of the tissue [46, 49, 50]. The epithelium was placed
over a 0.45 μm cellulose filter, with the connective side of the tissue facing the membrane filter,
due to its fragility [46, 47]. The membrane filter avoids epithelium damage, without altering
A Novel Mucoadhesive Film for Oral Mucosa Topical Anesthesia
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drug permeation. In addition, it reduces the release of impurities from the epithelium to the
receptor solution.
The mucoadhesive film, epithelium, and membrane filter were clamped between the donor
and receptor compartments. Saline-methanol (70:30, v/v) solution was used in the receptor
compartment in order to maintain the sink conditions. The experiment was performed at 37°C
during 5 h, under magnetic stirring (400 rpm). Samples (300 μL) were periodicallywithdrawn
from the receptor compartment and immediately replaced by the same volume of solution, tak-
ing account of dilution effects. The samples were transferred to chromatography vials and
stored in a refrigerator until GC-MS analysis for quantification of spilanthol.
The cumulative amount of spilanthol transported across esophagus epithelium per area unit
was plotted along time. The active steady-state flux (J) across the barrier was calculated from
the slope of the linear portion of the curve. The lag time was obtained from the intercept on the
time axis, and the permeability coefficientwas calculated according to the following equation
[46, 50, 51]:
J ¼ P  Cd
where J (μg.cm-2.h-1) is the spilanthol flux across the epithelium, P (cm.h-1) is the permeability
coefficient, and Cd is the spilanthol concentration in the donor compartment (μg/cm3). All
experiments were conducted six times.
2.7 In vivo Anesthetic Efficacy
2.7.1 Animals. Male Swiss mice (25–40 g) from the Multidisciplinary Center of Biological
Investigation of Laboratory Animals (CEMIB–UNICAMP)were maintained at 25 ± 2°C under
light/dark cycles of 12 h and were kept in their cages with water and food ad libitum for at least
7 days before the experiments. The trials were conducted after approval by the Animal Ethics
Committee of UNICAMP (protocol #2851–1) and in accordance with the Principles of Labora-
tory Animal Care (NIH publication #85–23, 1985). The mice were divided into groups of 5 to 6
animals, and each animal was used only once in the experiment.
2.7.2 Tail-flick test. The topical anesthetic efficacy of the mucoadhesive films containing
jambu extract was evaluated using the tail-flick test, as previously describedby de Araujo et al.
(2010) [51], which slightly modifiedGrant et al. (1993) method [52]. Briefly, the animal was
placed in an acrylic restraint while maintaining freely the distal portion of the tail (10 cm). The
time required for tail removal (latency) was considered as the aversive response to the heat gen-
erated by an incandescent lamp (55°C). The baseline was recorded for each animal before the
start of the experiment, and only those with baselines below 4 s were considered suitable. The
maximum time for contact of the tail with the heat source was set at 10 s (cut-off value) to
avoid thermal injury. The three mucoadhesive films prepared were compared to EMLA, used
as a positive control (150 mg/animal, corresponding to 7.5 mg of anesthetic) and a negative
control (chitosan-bioadhesive without the jambu extract). EMLAwas chosen due to its efficacy
to reduce pain during needle insertion [53–56] and during local anesthetic injection [57–59].
The mucoadhesive films and EMLA cream were applied 2 cm from the tail base, with the
aid of an adhesive tape, for 2 min. The tested substances were then removed, and the nocicep-
tive stimulus was applied to the same region.Measurements were performed immediately after
mucoadhesive removal and then every 15 min until the animal returned to its baseline pain
response. After use of the animals in the tail-flick test, they were euthanized by cervical disloca-
tion. The duration of analgesia was defined as the increase in the time required for withdrawal
of the tail, which was at least 50% higher than the baseline value observed.The data were
A Novel Mucoadhesive Film for Oral Mucosa Topical Anesthesia
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expressed as the percentage of the maximum possible effect (MPE, in minutes), using the fol-
lowing relation:
%MPE = [(test latency–baseline latency / cut-off time–baseline latency) x 100], being the
area under the curve (AUC) recorded for each experimental group [60].
3. StatisticalAnalysis
The in vitro permeation data were expressed as a percentage or mean ± SD and subjected to
one-way analysis of variance (one-way ANOVA) with the Holm-Sidak post hoc test. Analgesia
duration was analyzed by Kruskal-Wallis/SNK tests. Correlation between the in vivo efficacy
and the in vitro data was performed using the Pearson’s correlation test. All analyses were per-
formed using GraphPad Prism 6.01 (GraphPad Software, Inc., USA), considering a signifi-
cance level of 5%.
4. Results
4.1 Preparation of Extracts
The ethanolic crude extract of jambu yielded 7.7 ± 0.08%, while the crude extract treated with
4% activated carbon yielded 4.0 ± 0.03%, both on a dry basis. The yield decrease observed for
crude extract with 4% activated carbon did not affect the amount of spilanthol. In fact, the spi-
lanthol concentration was increased by using this procedure, being the greenish pigments
removed.
4.2 Characterizationof the Mucoadhesive Films
Table 1 shows the mean (±SD) values for thickness, mass, pH and spilanthol content obtained
during the mucoadhesive films stability study.
After 120 days of storage at 40°C, no significant degradation of spilanthol was verified in the
mucoadhesive films. The pH remained stable, with minimal changes.
4.3 In vitro Permeation Studies
Fig 3 shows the spilanthol permeation profiles of the different mucoadhesive films across pig
esophagus mucosa. The linear regression analysis showed higher (p< 0.0001) spilanthol per-
meation for 10% JBCmucoadhesive film in comparison with both 10% JB and 20% JB films,
which did not differ from each other (p = 0.474). Despite the 20% JB filmwas two-fold more
concentrated than 10% JB, the spilanthol permeation profiles of both were similar.
The permeation parameters (flux, lag time, and permeability coefficient) obtained for the
experiment illustrated in Fig 3 are provided in Table 2.
The 10% JBCmucoadhesive film presented higher flux of spilanthol across pig esophageal
mucosa when compared to both 10% JB (p = 0.0003) and 20% JB (p = 0.0004), which did not
Table 1. Physicochemical parameters (Mean±SD)of themucoadhesive films and spilantholextracted frommucoadhesive films.
Extracts Thickness(inmm)(n = 7) Mass (in g)(n = 7) pH (n = 3) Spilantholcontent (mg/g)
Day 0 Day 120 Day 0 Day 120
10% crudeextract 0.45 ± 0.02 0.13 ± 0.01 5.3 ± 0.03 5.4 ± 0.24 17.6 ± 1.41 16.7 ± 0.21
20% crudeextract 0.53 ± 0.01 0.14 ± 0.01 5.1 ± 0.02 5.1 ± 0.05 35.9 ± 5.59 36.2 ± 2.62
10% extract +4% activated carbon 0.52 ± 0.01 0.14 ± 0.01 4.9 ± 0.02 5.3 ± 0.05 22.9 ± 3.39 25.0 ± 0.85
Day 0 = the day of production; Day 120 = the maximumperiod in the climate chamber.
doi:10.1371/journal.pone.0162850.t001
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differ from each other (p = 0.8351). However, 10% JBCmucoadhesive film showed a signifi-
cantly longer lag time (p< 0.0001) than the other films. It also presented the highest perme-
ability coefficient (p< 0.01), while 10% JB film showed higher permeability coefficient than
20% JB (p = 0.0032).
4.4 Tail-Flick Test
Fig 4 shows the tail-flick test results, presented as the percentage of maximum possible effect
(%MPE).
Fig 3. Permeation profiles across pig esophagusmucosa of spilanthol frommucoadhesive films appliedunder finite dose conditions (mean ± SD,
n = 6). 10% JB: mucoadhesive containing 10% of dry crude extract; 20% JB: mucoadhesive containing 20% of dry crude extract; 10% JBC: mucoadhesive
containing 10% of dry extract treatedwith activated carbon (4%).
doi:10.1371/journal.pone.0162850.g003
Table 2. Parameters for the permeation (5 h) through pig esophageal mucosa, under finite dose conditions, of spilantholappliedusing the three
mucoadhesive films tested (mean ± SEM; n = 6; JB: dry crude extract; JBC: dry crude extract treatedwith 4% of activated carbon).
Mucoadhesive films(Spilanthol concentration) Flux(μg.cm2.h-1) Lag time(h) Permeability coefficient(×10-3cm.h-1)
10% JB (2.37mg) 9.18 ± 1.19a 0.16 ± 0.04a 3.86 ± 0.50a
20% JB (5.13mg) 9.52 ± 1.97a 0.25 ± 0.06a 1.84 ± 0.38b
10% JBC (3.14mg) 17.70 ± 4.36b 0.58 ± 0.15b 5.17 ± 1.39c
Each permeation parameter was analyzed separately by ANOVA/Holm-Sidak. Different lettersmean significant statistical differences (p<0.05) among the
mucoadhesive films.
doi:10.1371/journal.pone.0162850.t002
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The 10% JBCmucoadhesive film presented significantly higher (p< 0.001) area under the
curve (AUC0-105min) than the other formulations (Table 3).
As expected, no antinociceptive effect was observed in animals treated with chitosan
mucoadhesive films without dry crude extract of jambu (negative controls).
4.5 In vitro/In vivo Correlation
Fig 5 shows the Pearson coefficient (r) values for the correlation analysis between the perme-
ation parameters (flux and permeability coefficient) and duration of analgesia in the tail-flick
test. A strong correlation (r = 0.89) was found between analgesia duration and flux, but there
was no correlation with the permeability coefficient (r = 0.7).
Fig 4. Percentage of maximum possible effect (%MPE) values for the different formulations.Data are presented as mean ± SEM (n = 6). %MPE =
[(test latency–baseline latency / cut-off time–baseline latency) x 100].
doi:10.1371/journal.pone.0162850.g004
Table 3. Durationof analgesiaandAUC values for the three testedmucoadhesives and EMLA1.
Mucoadhesive films Analgesiaduration in minMedian (1st– 3rd quartiles) AUC(0–105 min)mean ± SD
10% JB (n = 6) 6.0 (2–10)a 230.4 ± 46.4 a
20% JB (n = 6) 30 (30–30)ab 417.3 ± 59.6b
10% JBC (n = 6) 60 (33.8–86.2)b 754.3 ± 131.2c
EMLA1 (n = 6) 75 (75–75)b 569.8 ± 160.0d
JB: dry crude extract; JBC: dry crude extract treatedwith 4% of activated carbon; Analgesia duration was analyzed by Kruskal-Wallis/SNK tests; AUC was
analyzed by ANOVA/Holm-Sidak tests. Each parameter was analyzed separately. Different lettersmean statistically significant differences among the films.
doi:10.1371/journal.pone.0162850.t003
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Fig 5. Pearson coefficientvalues (mean ± SD) for correlationbetween the studied factors and analgesiaduration.
Black circle: 10% JBC; white square: 20% JB; gray triangle: 10% JB.
doi:10.1371/journal.pone.0162850.g005
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5. Discussion
Spilanthol presents good stability in ethanolic extracts [61]. In addition, ethanol is relatively
safe, and it presents low toxicity and cost, being widely used in the extraction of natural prod-
ucts[62, 63]]. Therefore, ethanol was the solvent chosen to produce jambu extracts in the pres-
ent study. The crude jambu extraction yield obtained in this study is comparable to values
reported in other studies [64, 65].
Activated carbon has been used to remove chlorophyll or other compounds that might inter-
fere with colorimetric assays, and to isolate bioactive compounds [66, 67]. Activated carbon
includes a range of substances with a high degree of porosity and surface area around 800–1500
m2/g [68]. It has been also used in many applications, such as removal of color, taste, odor, and
other impurities in water [69], and in food processing [70], due to its excellent absorbance capac-
ity, biocompatibility, and lack of toxicity. In the present study, the use of activated carbonwas
effective to remove some crude extract pigments, such as chlorophyll. The 4% concentration
usedwas found to be the optimal percentage in a preliminary study. Despite the reduction in the
mass of extract, a relative increase in the spilanthol concentration was observed.
The mucoadhesive films showed homogeneity of thickness and mass. The average thickness
(0.5 mm) of the mucoadhesive films produced in this study was similar to that observedby
Aksungur et al. (2004) [71], who developed chitosan bioadhesives with nystatin to treat oral
mucositis. Storage at 40°C for 120 days did not affect the physical integrity, pH, or spilanthol
content of the adhesives, indicating the good stability of the formulations.
A vertical Franz diffusion cell is commonly used to evaluate the permeation of compounds
through the skin or mucosa [72]. The selection of porcine esophageal mucosa as the barrier in
this study was based on the similar histological characteristics of this tissue and oral mucosa,
such as the presence of non-keratinized stratified squamous epithelium, large surface area and
typically intact tissue, favoring the tissue handling during the Franz cells assembly [73].
The in vitro permeation of spilanthol in porcine oral mucosa has been investigated else-
where using Franz-type vertical diffusion cells. Boonen et al. (2010) [74] evaluated two formu-
lations of oral gel (Indolphar1 and Buccaldol1), as well as the pure ethanolic extract of jambu
with propylene glycol, using a porcine buccal mucosa (426 ± 10 μm) as permeation barrier.
The differences verified in the concentration of the active compound and the composition
of the formulation could lead to different permeation profiles. de Araujo et al. (2010) [51] eval-
uated multiple formulations of benzocaine, observed almost overlapping permeation profiles
in an infinite-dose design and a dramatically different behavior in a finite-dose condition. Boo-
nen et al. (2010) [74] and in the present study, similar permeation profiles of spilanthol were
obtained for the films, despite the substantial differences in spilanthol concentration and film
composition.
All the formulations evaluated in the current work permeated the pig esophageal epithelium
mucosa at higher flux rates than those describedby Boonen et al. (2010) [74]. This difference
could be explained by the thinner barrier used (mucosa epithelium rather than the thicker der-
matomized mucosa). In addition, higher spilanthol concentration (at least 10 times greater)
was used in our study, causing an increased flux of the active agent, in agreement with Fick’s
first law of diffusion.
Nevertheless, the flux is also influenced by the composition of the formulation [75]. Formu-
lations with different concentrations of the same drugmay exhibit the same flux, as observed
here for the 20% JB mucoadhesive film, which showed a flux very similar with the 10% JB film,
despite containing twice the spilanthol concentration. However, the 10% JBCmucoadhesive
film presented a flux almost two-fold higher than both 10% JB and 20% JB films, despite the
intermediate amount of spilanthol.
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These features can also be observed for the lag time and permeability coefficient,with for-
mulations containing the same concentration of the active agent, but different composition on
excipients, showing different solubility of the active compound during transport across the bar-
rier [51]. In the present case, the lag time and permeability coefficientwere higher for the 10%
JBCmucoadhesive film, compared to the other films. Similar findings were reported by Fang
et al. (2008) [76] who showed the addition of menthol and ethanol to tetracaine gels doubling
the flux and the lag time. The authors suggested that penetration enhancers acted to increase
the lag time due to slower distribution in the skin. Another possibility is the presence of a
higher concentration of terpenes in the 10% JBCmucoadhesive film, which are typically
observed in Acmella oleracea extracts [30], and cause an increase in the lag time and in the flux
of various drugs [77–79].
A longer lag time, however, should not be confusedwith a delay in the onset of the anes-
thetic effect in vivo, as demonstrated by Fang et al. (2008) [76]. They observed that a topical tet-
racaine formulation with the greatest lag time in vitro showed the shortest anesthetic onset
time in volunteers. The same profile was describedby Woolfson et al. (1998) [80], also using
tetracaine gel, where the lag time in vitro did not affect the in vivo onset of anesthesia. Similarly,
in the present study, the lag time did not have any effect on the beginning of analgesia in vivo.
Consequently, we hypothesize that the removal of pigments by the activated carbon treat-
ment was responsible for the better in vitro permeation results achieved with the 10% JBC
mucoadhesive. However, this hypothesis should be confirmed in further phytochemical stud-
ies. To the best of our knowledge, there are no studies regarding the effect of activated carbon
on the phytochemical composition of extracts from plants.
The tail-flick test has been demonstrated to be effective in the antinociceptive activity evalu-
ation of different topical formulations and mucoadhesive films [51, 81–83], and this assay was
chosen to evaluate the effectiveness of the mucoadhesive films in the present study.
The antinociceptive effect of jambu has been assessed previously using the tail-flick test.
Chakraborty et al. (2004) [39] demonstrated the analgesic activity of its aqueous extract after
intraperitoneal administration in albino rats at doses of 100, 200, and 400 mg/kg. Barman et al.
(2009) [84] reported the analgesic effect of an ethanolic extract of jambu after subcutaneous
administration to albino rats at a dose of 100 mg/kg. Interestingly, the antinociceptive effect
was observedwith only two minutes of application of the mucoadhesive film on the tail of the
animals, showing a rapid onset of action, as desired for dental procedures. The spilanthol con-
centrations in the mucoadhesive films (10% JB: 2.37 mg; 20% JB: 5.13 mg; 10% JBC: 3.14 mg)
were lower than the concentration of anesthetic in the positive control (EMLA1: 7.5 mg lido-
caine/prilocaine).
The correlation between in vivo effectiveness and in vitro drug permeation has been investi-
gated in several studies [51, 75, 85–88]. Since in vivo studies are usually more expensive,
involve ethical aspects, and are more time consuming than in vitro studies, efforts to standard-
ize the conditions of in vitro experiments and to achieve better replication during the evalua-
tion of different formulations have been performed [89]. The observation of a strong
correlation between the permeability coefficient and the duration of analgesia was in agreement
with other previous study [51], which observed the analgesia duration increasing with the
amount of benzocaine permeated across pig ear skin in vitro.
A strong correlation was also found between the flux and the duration of analgesia, which
could be explained by greater amounts of spilanthol reaching the receptors responsible for the
analgesic effect. In a previous study, Franz-Montan et al. (2013) [75] reported a strong correla-
tion between the flux of benzocaine across pig esophageal epithelium and anesthetic efficacy in
volunteers, although the duration of anesthesia was not reported.
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The molecular properties of spilanthol could also contribute to the results observed in the
present study since it meets all the requirements proposed by Lipinski et al. in 1997 [90], which
are known as "rule of five". The five requirements are set of parameters established to predict
whether a compound will or will not be orally bioavailable, being widely used to find newmole-
cules for drug development. These five requirements or rules are: 1) octanol-water partition
coefficient (log P) less than five; 2) molecular polar surface area (PSA) of 60 to 70 Å; 3) molecu-
lar weight should not exceed 500 g/mol; 4) less than 10 groups accepting hydrogen atoms to
form hydrogen bonds and 5) less than 5 groups in the molecule donating hydrogen atoms to
the hydrogen bonds. Spilanthol has log P of 3.4, PSA of 29.1, a molecular weight of 221 g/mol,
two atoms of hydrogen acceptors, and one hydrogen donor atom. Thus, it is likely to be perme-
able throughmembranes and it could be easily absorbed.
6. Conclusions
An orally mucoadhesive film based on chitosan appears to be a promising option for use as a
vehicle for the topical application of an anesthetic based on jambu ethanolic extract. The eth-
nopharmacological uses of this plant species, its use in the culinary area, its safety, and its low
toxicity indicate that it can provide an alternative to the topical anesthetic formulations cur-
rently available in dentistry.
The optimum formulation developed showed a high degree of in vitro permeation and an in
vivo anesthetic effect similar to EMLA, used as a gold standard topical anesthetic, indicating its
potential as an alternative to the topical anesthetics currently found on the market.
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